Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity

Alexandros Ardavanis; Stella Koumna; Ioannis Fragos; Savvoula Malliou; Flora Kyriakou; Ioannis Mantzaris; Andreas Scorilas; Gerassimos Rigatos

Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity

Alexandros Ardavanis, Stella Koumna, Ioannis Fragos, Savvoula Malliou, Flora Kyriakou, Ioannis Mantzaris, Andreas Scorilas, Gerassimos Rigatos

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

Original language	English (US)
Pages (from-to)	2409-2415
Number of pages	7
Journal	Anticancer Research
Volume	28
Issue number	4 C
State	Published - Jul 2008
Externally published	Yes

Keywords

Advanced non-small cell lung cancer
Erlotinib
Monotherapy

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{ce7824e9c8364f539a8a1551b0c839dc,

title = "Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity",

abstract = "Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.",

keywords = "Advanced non-small cell lung cancer, Erlotinib, Monotherapy",

author = "Alexandros Ardavanis and Stella Koumna and Ioannis Fragos and Savvoula Malliou and Flora Kyriakou and Ioannis Mantzaris and Andreas Scorilas and Gerassimos Rigatos",

year = "2008",

month = jul,

language = "English (US)",

volume = "28",

pages = "2409--2415",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "4 C",

}

TY - JOUR

T1 - Erlotinib monotherapy in patients with advanced non-small cell lung cancer

T2 - An effective approach with low toxicity

AU - Ardavanis, Alexandros

AU - Koumna, Stella

AU - Fragos, Ioannis

AU - Malliou, Savvoula

AU - Kyriakou, Flora

AU - Mantzaris, Ioannis

AU - Scorilas, Andreas

AU - Rigatos, Gerassimos

PY - 2008/7

Y1 - 2008/7

N2 - Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

AB - Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

KW - Advanced non-small cell lung cancer

KW - Erlotinib

KW - Monotherapy

UR - http://www.scopus.com/inward/record.url?scp=48849110458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849110458&partnerID=8YFLogxK

M3 - Article

C2 - 18751427

AN - SCOPUS:48849110458

SN - 0250-7005

VL - 28

SP - 2409

EP - 2415

JO - Anticancer Research

JF - Anticancer Research

IS - 4 C

ER -

Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this